HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of vancomycin and rifampicin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.

AbstractUNLABELLED:
Coagulase-negative staphylococci are the most common cause of late-onset sepsis in premature neonates. The optimal approach in persistent coagulase-negative staphylococcal bacteremia, despite adequate treatment with glycopeptides, is not well established. A retrospective study was conducted on preterm neonates with persistent coagulase-negative staphylococcal bacteremia treated with the combination of vancomycin-rifampicin. Ten cases were included, with a median gestational age of 26 weeks (range 24 weeks + 3 days-31 weeks + 4 days, interquartile range 25 weeks + 3 days-29 weeks + 3 days) and a median birth weight of 715 g (range 555-2,030). The median age at the onset of infection was 9 days (range 5-37). The most frequent clinical presentation was apnea or increased ventilatory support. Bacteremia persisted for a median of 9 (range 6-19) days until rifampicin initiation. Bacteremia was resolved in all cases on vancomycin-rifampicin with no serious side effects.
CONCLUSION:
Our study provides data supporting the safety and efficacy of vancomycin-rifampicin combination for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.
AuthorsLuciana Rodriguez-Guerineau, María Dolors Salvia-Roigés, Marisol León-Lozano, José Manuel Rodríguez-Miguélez, Josep Figueras-Aloy
JournalEuropean journal of pediatrics (Eur J Pediatr) Vol. 172 Issue 5 Pg. 693-7 (May 2013) ISSN: 1432-1076 [Electronic] Germany
PMID23328960 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Coagulase
  • Vancomycin
  • Rifampin
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Bacteremia (drug therapy, microbiology)
  • Coagulase
  • Drug Therapy, Combination
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Retrospective Studies
  • Rifampin (therapeutic use)
  • Staphylococcal Infections (drug therapy)
  • Staphylococcus (drug effects)
  • Treatment Outcome
  • Vancomycin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: